One thing in the presentation that I hadn't noticed before:
The lung cancer preclinical (which is probably being partnered) will be Zantrene + PD-1 inhibitor.
Phil has improved out of sight from the early days.
I'm not sure of the target audience. If I was new to RAC, this presentation wouldn't sell it to me by itself. The story takes many days of full-time DD for a new investor. But it's fine if the aim is to persuade existing investors to top up, e.g. in the SPP.
One thing in the presentation that I hadn't noticed...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |